Cyllene Therapeutics’ experimental gene therapy EG110A has received US FDA [...]
Doron Therapeutics has dosed the first patients in its Phase [...]
FDA recognises regenerative approach for congenital pseudarthrosis of the tibia [...]
Cyllene Therapeutics’ experimental gene therapy EG110A has received US FDA [...]
Doron Therapeutics has dosed the first patients in its Phase [...]
FDA recognises regenerative approach for congenital pseudarthrosis of the tibia [...]